Free CME

ScientiaCME Neuropsychiatry-Neurology contains 4 lectures:

• Parkinson’s disease: Highlights from the American Academy of Neurology 2017 Annual Meeting (AAN 2017)
• Migraine Headaches: Highlights from the American Academy of Neurology 2016 Annual Meeting (AAN 2016)
• Alzheimer Disease (AD) and Its Complications: Best Practices, Emerging Therapies, and Barriers to Care
• Multiple Sclerosis (MS) and Its Complications: Highlights from the AAN 2016 : Take-Aways, Emerging Practice Changes, and Barriers to their Implementation.

In order to get credit from ScientiaCME, you must first establish a username and password.

Target Audience: Neurologists

ScientiaCME Immunology-Rheumatology CME has two selections offering CME:

• Rheumatoid Arthritis (RA): Therapeutic Updates and Optimizing Treatment (1 hr CME)/li>
• Psoriatic Arthritis: Therapeutic Updates and Optimizing Treatment (1 hr CME)

Target Audience: Physicians focusing on Allergy, Rheumatology.

Scientia CME Critical Care – ERAS (Enhanced Recovery After Surgery) has six selections:

• Perioperative Goal Directed Therapy – What can we do outside the abdomen? (0.75 hr CME);
• Perioperative Goal-Directed Therapy-A Key Component of the Perioperative Surgical Home (PSH) (0.75 hr CME);
• Perioperative goal directed therapy: can we afford not to do it? (0.75 hr CME);
• Enhanced recovery after surgery (ERAS) in colorectal surgery: therapeutic updates, best practices, and barriers to care (1 hr CME);
• National Implementation of Enhanced Recovery in UK and next steps (0.75 hr CME);
• Surgical Quality Improvement (0.75 hr CME)

Target Audience:

Physicians focusing on Critical Care, General Surgery

Scientia CME Immunology – Allergy CME has two selections:

• Chronic Urticaria (CU): Therapeutic Updates, Best Practices, and Barriers to Care (1 hr CME);
• Psoriasis: Best Practices, Barriers to Care, and Emerging Therapies (1 hr CME)

Target Audience: Physicians focusing on Allergy or Dermatology

ScientiaCME Immunology contains a single lecture:
Therapeutic Updates, Best Practices, and Barriers to Care in the Treatment and Prevention of Kidney Transplant Rejection.

Target Audience:
Physicians specializing in Immunology, Nephrology, Urology

At the conclusion of By the end of Treatment strategies in Gaucher disease, you will be able to:

• Describe the importance of appropriate GD (Gaucher Disease) diagnosis and treatment (use • for bullets)
• Determine the likelihood of GD using with established diagnosis methods, given a patient case
• Describe present therapies for the treatment of GD and the literature supporting their use
• Design a medical plan to treat a patient with GD, taking into account presently available therapies

Target Audience:

Physicians focusing on Cardiology, genetic disorders, hematology, oncology, orthopedics, gastroenterology, neurology and pediatrics.

In this three-part program, our faculty explores case studies and delves into the diagnostic modalities and emerging therapies in the management of seasonal influenza.

• • Diagnosing Influenza
  • Treating Influenza
  • Flu in Motion: Case Presentation

Carcinoid Syndrome: Updates in Pathophysiology, Diagnosis, and Treatment consists of a single lecture and discussion by Drs. Matthew H. Kulke and C. Metz.

After viewing Carcinoid Syndrome, you will be better able to:
• Summarize the cause of carcinoid syndrome
• Perform an appropriate workup and differential diagnosis from presenting symptoms
• Adopt evidence-based best practices in managing carcinoid syndrome, including strategies to address refractory or poorly controlled symptoms
• Evaluate safety and efficacy of current and emerging treatment approaches for carcinoid syndrome

Target Audiences:
This program is intended for US-based medical oncologists, endocrinologists and gastroenterologists, as well as oncology physician assistants, nurse practitioners, and nurses involved in the diagnosis and management of carcinoid tumors and carcinoid syndrome.

Atypical hemolytic uremic syndrome (aHUS) is a disease in which the complement system is activated in an uncontrolled manner outside the presence of coexisting disease, resulting in platelet activation, damage to endothelial cells, and a range of clinical sequelae including: which may ultimately lead to kidney failure; systemic thrombotic microangiopathy;anemia; and thrombocytopenia.

After completing this course, you will better be able to:

• Describe the pathophysiology of aHUS such that it might informs pairing with present treatment mechanisms
• Describe aHUS diagnostic methods, differential diagnosis, and the benefits of earlier diagnosis
• Describe available therapies used for treatment of aHUS and summarize the literature supporting use of those therapies
• Design an evidence-based treatment plan for a patient with aHUS

Target Audience: hematologists, nephrologists, and primary care physicians; physician assistants, nurse practitioners, nurses, and pharmacists specializing in hematology and transplant medicine; and any other healthcare professionals with an interest in or who may clinically encounter patients with aHUS.

A 360° Approach to Translating MS Data into Optimal Practice focuses on practical topics, review clinical trial data with clarity and thoroughness, and incorporates cases to engage you on how this information can be used in clinical practice, for all disciplines involved in the care of patients with MS.

Upon completion of A 360° Approach to Translating MS Data into Optimal Practice, you should be better able to:
• Analyze data from clinical trials of disease modifying therapies to inform personalized treatment and monitoring of outcomes for patients with MS
• Access reliable and evidence-based resources in order to stay current with advances in the management of MS
• Integrate new and emerging information on the pathophysiology of MS, including modifiable risk factors, in the development of individualized treatment plans

Target Audience:
This educational initiative is intended to meet the needs of neurologists, nurses, nurse practitioners, physician assistants, rehabilitation professionals, case managers, mental health professionals, social workers and others involved in the management of patients with MS.